← back to search

Pavlo Gilchuk

AstraZeneca (Japan) · JP
Area of research
Infectious Diseases · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Viral Infections and Outbreaks Research, Monoclonal and Polyclonal Antibodies Research, and Viral gastroenteritis research and epidemiology.
h-index
40
citations
9,360
works
112
NIH funding
primary concept
Biology
email

Recent publications

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
CHEST Journal 2022cited by 30position: middledoi
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Nature Medicine 2021cited by 1,014position: middledoi
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Nature Microbiology 2021cited by 327position: middledoi
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature 2021cited by 260position: middledoi
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Cell Reports 2021cited by 112position: middledoi
Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface
2021cited by 1position: contributordoi
Potently neutralizing and protective human antibodies against SARS-CoV-2
Nature 2020cited by 1,190position: middledoi
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Cell Host & Microbe 2020cited by 1,143position: middledoi
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Nature Medicine 2020cited by 539position: middledoi
Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization
Immunity 2020cited by 95position: firstdoi
High frequency of shared clonotypes in human B cell receptor repertoires
Nature 2019cited by 338position: middledoi
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
Cell 2019cited by 266position: middledoi
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice
Cell Host & Microbe 2019cited by 70position: middledoi
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
Immunity 2018cited by 84position: firstdoi
A Distinct Lung-Interstitium-Resident Memory CD8+ T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract Infection
Cell Reports 2016cited by 75position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

James E. Crowe · Vanderbilt University Medical Center5 papers (2019–2021) · 3 papers (2019–2019) · 3 papers (2019–2019)Elad Binshtein · Vanderbilt University Medical Center2 papers (2020–2021)Hannah L. Turner · International AIDS Vaccine Initiative2 papers (2019–2019)Naveenchandra Suryadevara · Vanderbilt University Medical Center2 papers (2020–2021) · 2 papers (2019–2019)Xueyong Zhu · Scripps Research Institute2 papers (2019–2019)Andrew B. Ward · Scripps (United States)2 papers (2019–2019)Seth J. Zost · Lawrence Livermore National Security2 papers (2020–2021)Sheng Li · Sun Yat-sen University2 papers (2019–2019) · 2 papers (2019–2019)Ian A. Wilson · Raigmore Hospital2 papers (2019–2019)Robert H. Carnahan · Vanderbilt University Medical Center2 papers (2020–2021)Rachel E. Sutton · Vanderbilt University Medical Center2 papers (2020–2021)Sandhya Bangaru · Scripps Research Institute2 papers (2019–2019) · 1 papers (2016–2016) · 1 papers (2019–2019)Curtis A. Thorne · Southwestern Medical Center1 papers (2021–2021)Zhuoming Liu · Washington University in St. Louis1 papers (2020–2020)